Immunotherapy with Imiquimod Increases the Efficacy of Glucantime Therapy of Leishmania major Infection

Iranian Journal of Immunology

Volumn 8, Issue 1, 2011, Pages 45-51

  Khalili, Ghader ^a   Dobakhti, Faramarz ^b   Niknam, Hamid Mahmoudzadeh ^a   Khaze, Vahid ^a   Partovi, Fatemeh ^c  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

BALB c Mice; Glucantime; Imiquimod; Leishmania major

Indexed keywords

IMIQUIMOD; MEGLUMINE ANTIMONATE; AMINOQUINOLINE DERIVATIVE; ANTIPROTOZOAL AGENT; IMMUNOLOGICAL ADJUVANT; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FOOT PAD; IMMUNOTHERAPY; LEISHMANIASIS; MONOTHERAPY; MOUSE; NONHUMAN; PARASITE LOAD; THICKNESS; TREATMENT RESPONSE; ANIMAL; DRUG COMBINATION; LEISHMANIA MAJOR; PHYSIOLOGY; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTIPROTOZOAL AGENTS; DRUG THERAPY, COMBINATION; IMMUNOTHERAPY; LEISHMANIA MAJOR; LEISHMANIASIS; MEGLUMINE; MICE; MICE, INBRED BALB C; ORGANOMETALLIC COMPOUNDS; TREATMENT OUTCOME;

EID: 80052325216     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Walgate R, Simpson K, Modabber F, Leishmaniasis. Tropical diseases research progress 1991-1992. In: Walgate R, Simpson K, (Editors). Geneva: WHO; 1995. p. 77-88.
2. First WHO report on neglected tropical diseases: working to overcome the global impact of neglected tropical diseases. In: Crompton DWT, editor. Geneva, Switzerland: World Health Organization 2010; p. 91-6. Available from: http://www.who.int/neglected_diseases/2010report/en/
3. Molyneux DH, Killick-Kendrick R. Morphology, ultrastructure and life cycles. In:Peters W, Killick-Kendrick R, (Editors). The leishmaniasis in biology and medicine. Volume I. Biology and epidemiology. London: Academic Press; 1987. p. 121-76.
4. Olliaro PL, Bryceson AD. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 1993; 9:323-8.
5. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992; 46:296-306.
6. Davies CR, Kaye P, Croft SL, Sundar S. Leishmaniases: new approaches to disease control. BMJ. 2003; 326:377-82.
7. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators Imiquimod and S-28463: efficacy and mode of action. J Infect Dis. 1999; 179:1485-94.
8. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998; 76:25-32.
9. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis. 1997; 24:684-703.
10. Mayrink W, Botelho AC, Magalhaes PA, Batista SM, Lima Ade O, Genaro O, et al. Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop. 2006; 39:14-21.
11. Bogdan C, Rollinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol. 1998; 28:121-34.
12. Sundar S, Rosenkaimer F, Murray HW. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J Infect Dis. 1994; 170:659-62.
13. Squires KE, Rosenkaimer F, Sherwood JA, Forni AL, Were JB, Murray HW. Immunochemotherapy of visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon gamma. Am J Trop Med Hyg. 1993; 48:666-9.
14. Barroso PA, Marco JD, Calvopina M, Kato H, Korenaga M, Hashiguchi Y. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z -100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimonite. J Antimicrob Chemother. 2007; 59:1123-9.
15. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005; 174:1259-68.
16. Testerman TL, Gerster JF, Imberston LM, Reiter MJ, Miller RL, Gibson SJ, et al. Cytokine induction by the immunomodulators Imiquimod and S-27609. J Leukoc Biol. 1995; 58:365-72.
17. Dockrell DH, Kinghorn GR. Imiquimod and Resiquimod as novel immunomodulators. J Antimicrob Chemother. 2001; 48:751-5.
18. Brett PJ, Burtnick MN, Su H, Nair V, Gherardini FC. iNOS activity is critical for the clearance of Burkholderia mallei from infected RAW 264.7 murine macrophages. Cell Microbiol. 2008; 10:487-98.
19. Titus RG, Marchand M, Boon T, Louis JA. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 1985; 7:545-55.
20. Sypek JP, Chung CL, Mayor SE, Subramanyam JM, Goldman SJ, Sieburth DS, et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med. 1993; 177:1797-802.
21. Green SJ, Meltzer MS, Hibbs Jr JB, Nacy CA. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol. 1990; 144:278-83.
22. Murray HW, Delph-Etienne S. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun. 2000; 68:288-93.
23. Murray HW. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J Infect Dis. 1997; 175:1477-9.
24. El-On J, Bazarsky E, Sneir R. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod. Exp Parasitol. 2007; 116:156-62.